InflammaSense wins up to $38M ARPA-H grant for real-time immune monitoring
What's the deal? InflammaSenseDealroom has a profile for this one. Try Dealroom → has been selected as a performer under ARPA-H's CIRCLE program, making it eligible for up to $38 million in grant funding. The La Jolla-based medtech company will use the award to monitor and treat critically ill patients in intensive care units.
Why now? Sepsis affects around 4.6 million people in the US each year, often triggering organ failure. The CIRCLE program — Critical Illness Immunological Reprogramming and Control Point Learning Engine — targets the immune dysregulation behind those outcomes.
What's the endgame? CIRCLE follows a measure-model-modulate framework: collect real-time data on immune trajectories, build patient-specific computational models, then intervene at key immune control points before organs fail.
The product. InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to track autonomic and inflammatory signatures in up to 200 patients across three clinical sites. The data feeds into its Autonomic Research Core, which sorts patients by immune trajectory using a cascade-endotyping classifier.
The technology stems from research at the University of California, San Diego. It detects immune responses through cervical Autonomic Neurography, using magnetoneurography and electroneurography to monitor the autonomic nervous system in real time.
What they said. "The CIRCLE program gives us a path to validate ANG at scale in the population it was designed to serve," said Imanuel Lerman, chief executive officer and founder. He added that detecting "sepsis hyperimmune or immunoparalysis is notoriously challenging with current tools."
The signal: At $38 million, the award ranks among the largest health grants in the US, sitting in the 99th percentile of some 7,000 comparable rounds. It reflects growing bets on data-driven, personalised monitoring to manage life-threatening conditions.
Read more: third-news.com
Image credit: Generated with Gemini
